DGAP-News: co.don AG

CO. DON AG - Capital increase successfully completed

+ Largest capital increase since IPO

Berlin / Teltow, October 26, 2017 - With the successful completion of the capital increase resolved on October 19, 2017, CO. DON AG received approx. EUR 15.5 million. The capital increase was executed with the exclusion of shareholders' subscription rights and was aimed exclusively at institutional investors. The company's share capital increased to EUR 19,460,812.00.
Dirk Hessel, CEO of CO.DON AG: "On behalf of the entire CO.DON, I would like to thank for the larginterest in the investment, which is also an expression of confidence in the presented business case. Our investor base has further strengthened and internationalised. This is the largest capital increase since the company's IPO. Now we are on the threshold of the company's next stage of development: The funds we have acquired - apart from the faster and broader market penetration of the EU market for our product Spherox - also give us the prerequisite for the construction of a modular, scalable production plant at a new location in Germany. In addition to the redundancy for our existing plant in Teltow, this will also create capacity for the expected rising demand from the EU area. With the completion of the plant, we will be one of the world's largest producers of industrial-scale, autologous cells. Our strategy is set: with our product, we are clearly positioning ourselves in the field of regenerative arthrosis prophylaxis with the goal of European market leadership. We also have markets outside the EU's economic area in mind."

About CO.DON AG: CO.DON AG develops, produces and markets autologous cell therapies for the minimally invasive repair of cartilage damage in knee joints following traumatic or degenerative defects. The product being marketed is a cell therapy product that uses only the patient's own cartilage cells ("autologous chondrocytes"). CO.DON's method has been used for more than 10 years in over 150 clinics to treat more than 11,000 patients. In Germany the statutory health insurance companies have paid for the treatment of knee and hip joints since 2007. In July 2017 the company received EU marketing authorisation for Spherox. The shares in CO.DON AG are listed on the Frankfurt Stock Exchange (ISIN: DE000A1K0227). Executive Board: Dirk Hessel (CEO), Ralf M. Jakobs (CFO).
More information can be found at www.codon.de

Investor Relations and Press Contact:
Matthias Meißner, M.A.
Corporate communications / IR / PR
Tel. +49 (0)30 240352330
Fax +49 (0)30 240352309
Email: ir@codon.de